Frontiers in allergy最新文献

{"title":"Determining the role of basophil activation testing in reported type 1 allergy to beta-lactam antibiotics.","authors":"Markus Reitmajer, Antonia Strauss, Christian Klinger, Maximiliane Maaß, Wolfgang E Kempf, Joerg Fischer, Manfred Kneilling, Sebastian Volc","doi":"10.3389/falgy.2024.1512875","DOIUrl":"https://doi.org/10.3389/falgy.2024.1512875","url":null,"abstract":"<p><strong>Background: </strong>Allergy to beta-lactam antibiotics (BLA), especially to penicillin, is the most commonly reported drug allergy by patients. Alternative antibiotics can yield negative consequences, such as extended hospitalization days due to less efficacy and overall higher costs. The basophil activation test (BAT) is an <i>in vitro</i> assay, in which activation of an individual's own basophils is quantified by flow cytometry. It is an increasingly applied <i>in vitro</i> method in allergy testing that is also gaining traction in drug allergies.</p><p><strong>Methods: </strong>We correlated 37 BAT results with skin test results. The cohort exclusively included patients with suspected type I BLA allergy. In addition, we examined the concordance of these results with clinical symptoms reported in the BLA patients' medical histories.</p><p><strong>Results: </strong>BLA-BAT revealed a high specificity of 92.3% [95% confidence interval (CI) 66.7-98.6] but a low sensitivity of only 20.8% (95% CI 9.24-40.47) using BLA-skin tests as a comparator. Negative BLA-BAT in patients with a history of grade I anaphylaxis yielded doubt on the assumption of grading. The exclusion of grade I BLA anaphylaxis increased the sensitivity to 29.4% (95% CI 13.28-53.13) with a still high specificity of 85.7% (95% CI 48.69-97.43). When ImmunoCAP was available, we compared specific IgE and BAT results by using Cohens' kappa (κ) and revealed a moderate level of agreement (κ = 0.538, <i>p</i> = 0.029).</p><p><strong>Conclusion: </strong>BAT reveals specific positive results exclusively in patients with cephalosporin anaphylaxis. However, these findings could not be generally confirmed in the heterogeneous group of BLA.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1512875"},"PeriodicalIF":3.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Animal models of allergic diseases: from basic to preclinical research.","authors":"Friederike Jönsson, Diego Pazos-Castro, Margarida Castell, Pål Johansen","doi":"10.3389/falgy.2024.1526536","DOIUrl":"10.3389/falgy.2024.1526536","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1526536"},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infants born during COVID-19 pandemic experience increased susceptibility to airway hyperresponsiveness.","authors":"Idit Lachover-Roth, Anat Cohen-Engler, Yael Furman, Yossi Rosman, Keren Meir-Shafrir, Michal Mozer-Mandel, Sivan Farladansky-Gershnabel, Tal Biron-Shental, Ronit Confino-Cohen","doi":"10.3389/falgy.2024.1512182","DOIUrl":"10.3389/falgy.2024.1512182","url":null,"abstract":"<p><strong>Background: </strong>Asthma, allergic rhinitis, atopic dermatitis, and food allergy are type 2 inflammation diseases. Since the 1960s, the prevalence of those diseases has steadily increased, presumably due to the \"Hygiene hypothesis\" which suggests that early exposure of infants to pathogens, siblings, and environmental dust, has a protective effect against the development of allergic diseases. The COVID-19 pandemic increased environmental hygiene due to lockdowns, masks, and social distancing.</p><p><strong>Objective: </strong>To compare the prevalence of allergic diseases among children born before and during the pandemic.</p><p><strong>Methods: </strong>The Cow's Milk Early Exposure Trial prospectively followed newborns until 12-months of age using monthly survey and examined milk allergy development. Some were born before the first COVID-19 lockdown in Israel (April 2018-March 2020), and some were born during the pandemic (March 2020-May 2021). The monthly surveys included questions regarding atopic comorbidities.</p><p><strong>Results: </strong>A total of 1,989 infants completed 12-months of follow-up. Among them, 1,086(54.5%) were diagnosed with at least one atopic disease. Among 235 infants born after the last lockdown, 162 were diagnosed with airway hyperresponsiveness (AHR)(68.9%), significantly more than in any other group. No other significant differences were found between the study groups.</p><p><strong>Conclusions: </strong>There was no significant difference in the development of atopic comorbidities between infants born before and during the pandemic. Significantly more infants who were born after restrictions were eased were diagnosed AHR. A longer follow-up period is needed to obtain a better understanding of the influence of the COVID-19 restrictions on the development of atopic comorbidities.</p><p><strong>Clinical trial registry: </strong>NIH Clinical Trials Registry: NCT02785679.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1512182"},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Drug allergy in children.","authors":"Mara Morelo Rocha Felix, José Laerte Boechat, Fábio Chigres Kuschnir, Mariana C Castells","doi":"10.3389/falgy.2024.1530907","DOIUrl":"10.3389/falgy.2024.1530907","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1530907"},"PeriodicalIF":3.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11684478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned.","authors":"D M Conti, V Backer, W Fokkens, P Gevaert, A Peters, G K Scadding, I Pavord, S Lau, M Wechsler, X Bertels, G Liva, M Doulaptsi, E Prokopakis, P W Hellings","doi":"10.3389/falgy.2024.1517122","DOIUrl":"10.3389/falgy.2024.1517122","url":null,"abstract":"<p><p>The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1517122"},"PeriodicalIF":3.3,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The increasing role of the allergist in the management of infusion reactions at the Oncology Infusion Center.","authors":"Julián Borrás Cuartero, Maria Cruz Torres Górriz, Cristina Isabel Stein Coronado, Adrián Germán Sánchez, Cristina Giovanna Pesántez Méndez, Maria Dolores Latorre Ibáñez, Ernesto Enrique","doi":"10.3389/falgy.2024.1479469","DOIUrl":"10.3389/falgy.2024.1479469","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reactions to chemotherapy disrupt treatment schedules and compromise patient outcomes. Rapid Drug Desensitization (RDD) enables patients to tolerate future treatments after an allergy workup. However, Same-Day Desensitization (SDD) is a novel approach that capitalizes on RDD to allow the continuation of chemotherapy on the same day as the index reaction, preventing treatment delays.</p><p><strong>Objective: </strong>To evaluate the safety and efficacy of SDD in managing hypersensitivity reactions during chemotherapy and emphasize the essential role of allergists in the Oncology Infusion Center (OIC) for accurate drugs hypersensitivity reactions (DHRs) phenotyping and management.</p><p><strong>Methods: </strong>This retrospective cohort included patients experiencing DHRs during chemotherapy. Under allergist supervision, SDD was performed once the index reaction was controlled. At a later date, clinical phenotypes and endotypes of DHRs were assessed through clinical history, skin tests, serum biomarkers (including tryptase and IL-6 levels), and drug provocation testing (DPT) to reach an accurate diagnosis.</p><p><strong>Results: </strong>SDD was successful in 35 cases, even for patients with severe initial reactions. Only 14% experienced breakthrough reactions, all mild. Same-day assessment by allergists ensured a 92% correlation between initial and final diagnoses, optimizing DHR management. Early engagement with Allergy allowed 86% of reactive patients to continue treatment through RDD or after ruling out an allergy.</p><p><strong>Conclusion: </strong>SDD is a safe and effective procedure that ensures that patients don't miss their oncology treatment on the day of a reaction. The presence of an allergist in the OIC is crucial for rapid access to accurate DHR phenotyping and optimal management, supporting personalized precision medicine in oncology.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1479469"},"PeriodicalIF":3.3,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: New insights in pediatric gastrointestinal food allergies.","authors":"Laura Carucci, Neil Shah, Roberto Berni Canani","doi":"10.3389/falgy.2024.1531494","DOIUrl":"10.3389/falgy.2024.1531494","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1531494"},"PeriodicalIF":3.3,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk and protective factors for coronavirus disease 2019 (COVID-19) in allergic rhinitis patients: a national survey in China.","authors":"Xiaozhe Yang, Yutong Sima, Jinming Zhao, Jing Zhang, Xiangdong Wang, Luo Zhang","doi":"10.3389/falgy.2024.1479493","DOIUrl":"10.3389/falgy.2024.1479493","url":null,"abstract":"<p><strong>Background: </strong>Several epidemiological studies have shown that allergic rhinitis (AR) patients are more susceptible to coronavirus disease 2019 (COVID-19).</p><p><strong>Objective: </strong>We aim to investigate the risk factors for COVID-19 in AR patients.</p><p><strong>Methods: </strong>A retrospective nationwide cohort study was conducted based on a questionnaire survey in China. The baseline characteristics, region of residence, smoking and drinking status, comorbidities, vaccination status and previous infection information were obtained. Allergen test results, the SARS-CoV-2 nucleic acid test, and antigen detection results were collected. Information on AR and comorbid medication use pre-SARS-CoV-2 infection was also collected. Binary logistic regression and analysis of covariance (different adjusted models) were conducted.</p><p><strong>Results: </strong>In all, 830 AR patients were included; 627 patients (75.54%) were infected with SARS-CoV-2. AR comorbid with allergic conjunctivitis (AC) was a protective factor [OR: 0.525 (95% CI = 0.296-0.929), <i>P</i> = 0.027] against SARS-CoV-2 infection, while AR comorbid with food allergy was a risk factor [OR: 6.404 (95% CI = 1.349-30.402), <i>P</i> = 0.0195]. Although fewer patients received four doses of the vaccine, the results showed a significant protective effect against SARS-CoV-2 infection in AR patients [OR: 0.093 (95% CI = 0.025-0.348), <i>P</i> = 0.0004]. Underweight was a protective factor against COVID-19 [OR: 0.287 (95% CI = 0.147-0.562), <i>P</i> = 0.0003] after full multivariable adjustment. Overweight was associated with a 2.071-fold higher risk for COVID-19 compared with normal weight [(95% CI = 1.045-4.105), <i>P</i> = 0.0370]. Additionally, house dust mite (HDM)-specific allergies were also protective against COVID-19 [OR: 0.537 (95% CI = 0.290-0.996), <i>P</i> = 0.0484].</p><p><strong>Conclusions: </strong>This study revealed underlying protective and risk factors, which might be used to improve the management of AR and COVID-19.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1479493"},"PeriodicalIF":3.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic characteristics associated with a penicillin allergy label during pregnancy.","authors":"Timothy M Buckey, Patrick K Gleeson, Cara M Curley, Scott F Feldman, Andrea J Apter, Olajumoke O Fadugba","doi":"10.3389/falgy.2024.1511392","DOIUrl":"10.3389/falgy.2024.1511392","url":null,"abstract":"<p><strong>Introduction: </strong>Penicillins and other beta-lactam antibiotics are used in greater than one-third of pregnant women as treatment for Group B Streptococcus colonization and prophylaxis for Caesarean sections. Penicillin allergy labels have been associated with increased morbidity in the pregnant population, and penicillin allergy evaluation during pregnancy is now recognized as safe and effective. Yet, demographic characteristics associated with having a penicillin allergy label during pregnancy have not been studied. We aimed to evaluate factors associated with having a penicillin allergy label in a diverse population of pregnant patients.</p><p><strong>Methods: </strong>We performed a retrospective observational study of pregnant patients who had an outpatient visit with Obstetrics and Gynecology and a delivery encounter from 1/1/2020 through 6/30/2022 using electronic health record data in a large health system. We used a multivariable logistic regression model to evaluate factors associated with having a penicillin allergy label.</p><p><strong>Results: </strong>We identified 10,969 pregnant women of whom 940 (8.6%) had a penicillin allergy label. In the multivariable analysis, having a penicillin allergy label was positively associated with age 32-34 years [odds ratio (OR) = 1.31 vs. 18-27 years, <i>p</i> = 0.02], 35-51 years (OR = 1.41 vs. 18-27 years, <i>p</i> = 0.002) and having rhinitis, asthma, or eczema (OR = 1.55 vs. none, <i>p</i> < 0.0005); and negatively associated with Black race (OR = 0.59 vs. White, <i>p</i> < 0.0005).</p><p><strong>Discussion: </strong>This study found that Black race was associated with lower likelihood of penicillin allergy label, while older age and atopic conditions were associated with a higher likelihood. This finding may impact health outcomes and interventions related to penicillin allergy in pregnant women.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1511392"},"PeriodicalIF":3.3,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acupuncture for allergic rhinitis: protocol for a systematic review and network meta-analysis.","authors":"YanNi Chen, ChenFei Song, JiaQin Wang, XinMin Han","doi":"10.3389/falgy.2024.1499406","DOIUrl":"10.3389/falgy.2024.1499406","url":null,"abstract":"<p><strong>Introduction: </strong>Allergic rhinitis (AR) is a widespread inflammatory disorder of the nasal mucosa affecting millions globally. The increasing prevalence of AR underscores the need for effective treatment modalities. Acupuncture has been identified as a potential non-pharmacological intervention for AR due to its effects on autonomic nerve functions and neuroendocrine and immune networks. However, a comprehensive evaluation of different acupuncture techniques through high-quality, evidence-based research is still needed.</p><p><strong>Methods and analysis: </strong>Randomised controlled trials of different acupuncture-related therapies for postmenopausal osteoporosis will be searched in the following databases from 1 January 2002 to 31 December 2022, including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, VIP Database, Wanfang Database and China Biomedical Literature Database. Overall, clinical efficacy rate, bone mineral density and a Visual Analogue Scale score are used as the primary outcome indicators. In addition, the secondary outcome indicator is adverse reactions. Meanwhile, Stata (V.14.0) and RevMan (V.5.4) will be used to conduct the network meta-analysis. If the data are permissible and feasible, we will also perform meta-regression and subgroup analyses to address the underlying causes of data inconsistency and heterogeneity in the statistical analyses. To improve the credibility of this network meta-analysis, we will evaluate the quality of evidence in this research according to the GRADE assessment. <b>Prospero Registration Number</b>: identifier (CRD 42024579713).</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1499406"},"PeriodicalIF":3.3,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}